We recently demonstrated that the prognosis for de novo CD5-positive (CD5+) diffuse large-B-cell lymphoma (DLBCL) is markedly worse than that for CD5-negative (CD5-) DLBCL. Our findings also suggested that on the basis of its clinical features CD5+ DLBCL may constitute a unique disease category. However, the genetic basis for these two categories has not been established. Therefore, we performed comparative genomic hybridization analysis (CGH) of 26 cases of CD5+ DLBCL and 44 cases of CD5- DLBCL. Several identical changes in CD5+ and CD5- DLBCLs were found, such as gains of 3q, 9p, 12q, 13q, and 18q and losses of 1p, 6q, 17p, and 19p. However, distinct differences between the two categories were also detected. These included gains of 11q21-q24 (P=0.032) and 16p (P=0.005) in CD5+ DLBCL, and loss of 16p (P=0.028) in CD5- DLBCL. A comparison with results reported for mantle cell lymphoma, chronic lymphocytic leukemia, and Richter's syndrome demonstrated that the CGH pattern of CD5+ DLBCL was markedly different. This indicates that CD5+ DLBCL constitutes a disease category distinct from that of CD5- DLBCL and other CD5+ malignancies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/gcc.10298 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients.
Ann Hematol
January 2025
Department of Pharmacy, Harbin Medical University Cancer Hospital, 150086, Harbin, China.
The purpose of this study was to comprehensively analyze the prediction role of NADPH oxidase (NOX)-related polymorphisms (NCF4: rs1883112, CYBA: rs4673, RAC2: rs13058338) and immunohistochemical indices on survival in diffuse large B-cell lymphoma (DLBCL).The impact of NOX polymorphisms were evaluated in 335 DLBCL patients treated with R (rituximab)-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) from Harbin Medical University Cancer Hospital. We also collected information on their immunohistochemical expression and clinical outcomes.
View Article and Find Full Text PDFPrimary large B-cell lymphoma of the central nervous system: A reappraisal of CD5-positive cases based on clinical, pathological, and molecular evaluation.
Pathol Int
December 2024
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
CD5 expression is seen in 5%-10% of de novo diffuse large B-cell lymphomas (DLBCLs). Primary large B-cell lymphoma of the central nervous system (PCNS-LBCL) also exhibits CD5 expression in a minority of cases, however, clinicopathological and molecular features remain largely unclarified. Here we present the clinical, molecular, and pathological features of 11 CD5-positive () PCNS-LBCL cases, occupying 6.
View Article and Find Full Text PDFErythema Nodosum Secondary to CD5-Positive Diffuse Large B-Cell Lymphoma as a Paraneoplastic Symptom: A Case Report.
Case Rep Oncol
September 2024
Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan.
Introduction: Erythema nodosum (EN) is the most common form of panniculitis. EN can be idiopathic or secondary to an underlying systemic disease, infection, drug use, or tumor. CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is a relapsed and refractory lymphoma, and further understanding of its pathology is required.
View Article and Find Full Text PDFTonsillar Diffuse Large B-Cell Lymphoma of Non-Germinal Center Type With Cluster of Differentiation 5 Positive in a Pediatric Girl.
J Med Cases
November 2024
Collage of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Lymphoma is a common malignancy in children. It is the second most common malignancy in children older than 1 year of age. Most extranodal non-Hodgkin lymphoma (NHL) in the head and neck is usually caused by diffuse large B-cell lymphoma (DLBCL), but pediatric DLBCL with cluster of differentiation (CD)5 expression is rarely discussed in the literature.
View Article and Find Full Text PDFRecent advances in CD5 diffuse large B-cell lymphoma.
Ann Hematol
November 2024
Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China.
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma, with a rare subset known as CD5 DLBCL, affecting about 5-10% of patients and often presenting in older females with more severe disease symptoms.
- CD5 DLBCL patients tend to have poorer prognostic factors, such as higher levels of lactate dehydrogenase and advanced disease with increased risks of central nervous system relapse and bone marrow involvement.
- Traditional treatments like R-CHOP are less effective for CD5 DLBCL, prompting interest in newer therapies, including BTK inhibitors and immunotherapy, though further research is needed to ascertain the best treatment approaches.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!